Biography for Alison Bryant
Alison Bryant began at FierceVaccines in 2012. She has covered local politics, growth and development and breaking news in Maryland and Vermont. Her work has been published in The Washington Post, The Burlington Free Press and The Gazette. In her free time, Bryant enjoys reading, creative writing and yoga. She's based in Washington, D.C. and can be reached at firstname.lastname@example.org. Follow @AlisonBFierce on Twitter.
- Contact Alison
- Follow Alison on Google+
Articles by Alison Bryant
A new study completed by researchers at the University of North Carolina demonstrated injecting non-obese diabetic mice with nondepleting antibodies rapidly reversed Type 1 diabetes.
Researchers at the Boston hospital say they discovered a new vaccine candidate that aims to fight infections, like Pseudomonas aeruginosa.
In an effort to cut costs, Indonesia's PT Bio Farma will start producing a vaccine for the bird flu virus by 2013.
A few new Salmonella Typhi vaccines use live attenuated strains of the bacteria, but such methods can mean the salmonella is shed into the environment through excrement. Researchers at Arizona State University's Biodesign Institute have been researching ways to detect S. Typhi--the cause of typhoid fever--in feces after use of the vaccine.
GlobeImmune has detailed plans for a $69 million IPO, aiming to rally public investors to back development of its therapeutic vaccines.
The FDA approved Argos Therapeutics' a revised Special Protocol Assessment (SPA) for its Phase III clinical study of AGS-003 for the treatment of metastatic renal cell carcinoma, or kidney cancer.
About 700,000 children in the Philippines will receive a rotavirus vaccination, thanks to a national immunization program for children.
Soligenix, a Princeton, NJ-based biopharmaceutical company, will partner with the Infectious Disease Research Institute of Seattle, to develop biodefense vaccines.
Production of a dengue vaccine could cost mere pocket change, according to an economic analysis completed by the Dengue Vaccine Initiative. Producing a tetravalent dengue vaccine could cost as little as 20 cents per dose, with an annual production level of 60 million doses packaged in 10-dose vials.
An experimental vaccine could smother a smoker's addiction to nicotine. Researchers at Weill Cornell Medical College developed and successfully tested in mice a vaccine to treat such dependence.